FDA weighs esketamine for depression
Update: 2019-02-15
Description
Contact us: podcasts@mdedge.com
- FDA panels back intranasal esketamine for refractory depression.
http://bit.ly/2TOKrfp - ONC aims to help doctors, patients with information sharing in proposed rule.
http://bit.ly/2X3SVkP - Survey: Health care costs unlikely to improve in 2019.
http://bit.ly/2SwSIYJ - Vaccination and antiviral treatment don't lower stroke risk after shingles.
http://bit.ly/2tjYQVa
Comments
In Channel














